首页|分化型甲状腺癌放射性碘治疗的文献计量可视化分析

分化型甲状腺癌放射性碘治疗的文献计量可视化分析

扫码查看
目的 通过文献计量可视化分析对2014-2023年期间分化型甲状腺癌(differentiated thyroid cancer,DTC)放射性碘治疗的研究现状进行分析,以了解该领域的研究热点和未来发展.方法 使用Web of Science数据库,筛选出2014-2023年期间发表的DTC放射性碘治疗相关文献.利用RStudio、Flourish等软件对文献发布时间、国家、机构、作者、关键词等内容进行分析,构建多维科研网络并进行可视化分析.结果 共筛选出2014-2023年期间发表的2018篇DTC放射性碘治疗研究相关文献,发表文献数量(简称"发文量")呈波动性增长趋势,发文量中国居首位(422篇),其次是美国和意大利(分别为374篇和182篇).在国家间合作方面,美国主导合作居世界首位(289次),与美国合作次数排名前3位的国家分别是意大利(33次)、中国(21次)和法国(21次);我国主导的合作相对较少(共计52次),排名第5位,合作对象主要集中在日本(7次)、韩国(6次)和澳大利亚(5次).发文量前6位的机构有一半来自美国,其中前3位的机构分别是来自法国的Unicancer(135 篇)、美国的 Memorial Sloan Kettering Cancer Center(134 篇)和美国的 UT MD Anderson Cancer Center(89篇);我国的北京协和医院和上海交通大学位列第19和23位,发文量分别为46篇和44篇.发文量排名前10位的作者中,来自美国的Tuttle RM作者发文量和贡献量均排名第1位,他在2014-2023年间共发表了48篇论文;我国林岩松和谭建2位医生进入发文量排名前10位,发文量分别为32篇和25篇.主题趋势呈现出热点的演变历程,从尿碘与DTC的关系、淋巴结转移,到创新研究、预后评估,以及碘难治性DTC新疗法等方面.关键词的共现和聚类包含了4个方面,分别是DTC的规范化管理、围治疗期的相关内容、乳头状甲状腺癌及DTC碘难治性靶向治疗的探索.结论 近年来,DTC碘治疗领域的研究热点从技术应用转向管理理念,这也促进了治疗模式的提升,患者的治疗方案愈发个体化和精准化.未来研究将集中在精准医疗、个体化治疗、靶向和免疫治疗的结合、治疗抵抗机制、治疗后的长期管理等方面,旨在改善患者的治疗效果和生活质量,实现治疗的革命性突破.
Radioactive iodine therapy for differentiated thyroid cancer:a visualized bibliometric analysis
Objective To analyze the current research status of radioactive iodine(RAI)therapy for differentiated thyroid cancer(DTC)in the past 10 years so as to understand the research hotspots and future development in this field through a bibliometric visualization analysis.Methods The literature relevant DTC RAI therapy published from 2014 to 2023 was screened using the Web of Science database.The publication time,country,institution,author,keywords,and other content of literature were analyzed,and the multidimensional scientific research network was constructed,and the visualization analysis was performed using RStudio and Flourish software.Results A total of 2 018 studies related to DTC RAI therapy were screened out from the publications from 2014 to 2023,with a fluctuating trend of increasing publication numbers.The publication numbers in China ranked first(422 articles),followed by the United States(374 articles)and Italy(182 articles).In terms of international cooperation,the United States ranked first with the most leading collaborations(289 times),and the top 3 countries in terms of cooperation with the United States were Italy(33 times),China(21 times),and France(21 times).China ranked fifth in leading cooperation,relatively less(52 times),with the main collaborators being Japan(7 times),South Korea(6 times),and Australia(5 times).Half of the top 6 institutions in terms of publication numbers were from the United States,with the top 3 being Unicancer from France(135 articles),Memorial Sloan Kettering Cancer Center from the United States(134 articles),and the UT MD Anderson Cancer Center from the United States(89 articles).Beijing Union Medical College Hospital and Shanghai Jiao Tong University ranked 19th and 23rd,respectively,with article counts of 46 and 44 articles.Tuttle RM,an author from the United States,ranked first in both publication numbers and contribution,with a total of 48 articles published from 2014 to 2023.There were two authors,Lin YS and Tan J,from China who had made it into the top 10 in terms of publication numbers,with 32 and 25 publications,respectively.The trend topics showed the evolution of hot topics,covering from the relation between urinary iodine and DTC,lymph node metastasis,to innovative research and prognosis assessment,as well as in-depth exploration of new therapies for iodine-refractory DTC.The co-occurrence and clustering of keywords included 4 aspects,namely,the standardized management of DTC,related contents during the peri-treatment period,papillary thyroid carcinoma,and the exploration of targeted therapy for iodine-refractory DTC.Conclusions In recent years,the research focus in the field of DTC RAI therapy has shifted from technical applications to management concepts,which has also promoted the improvement of treatment modes and made patients'treatment plans increasingly personalized and precise.Future research will focus on precision medicine,individualized treatment,the combination of targeted therapy and immunotherapy,resistance mechanisms to treatment,and long-term management after treatment,aiming to improve patients'treatment outcomes and quality of life and achieve a revolutionary breakthrough in treatment.

differentiated thyroid cancerradioactive iodine therapybibliometric analysis

张芸瑞、张鑫、张迎强、林岩松

展开 >

中国医学科学院北京协和医学院北京协和医院核医学科疑难重症及罕见病国家重点实验室(北京 100730)

核医学分子靶向诊疗北京市重点实验室(北京 100730)

首都医科大学附属第八临床医学院(北京 100038)

分化型甲状腺癌 放射性碘治疗 文献计量分析

北京协和医院中央高水平医院临床科研专项

2022-PUMCH-B-072

2024

中国普外基础与临床杂志
四川大学华西医院

中国普外基础与临床杂志

CSTPCD
影响因子:0.858
ISSN:1007-9424
年,卷(期):2024.31(8)
  • 9